Cargando…
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (...
Autores principales: | Han, Hui-Ju, Liu, Jian-Wei, Yu, Hao, Yu, Xue-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315345/ https://www.ncbi.nlm.nih.gov/pubmed/30513619 http://dx.doi.org/10.3390/v10120680 |
Ejemplares similares
-
Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus
por: Han, Hui-Ju, et al.
Publicado: (2016) -
Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
por: Sivapalasingam, Sumathi, et al.
Publicado: (2021) -
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
por: Payne, Daniel C., et al.
Publicado: (2016) -
Antibodies and vaccines against Middle East respiratory syndrome coronavirus
por: Xu, Jiuyang, et al.
Publicado: (2019) -
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
por: Xiang, Rong, et al.
Publicado: (2022)